Prostate cancer screening tool leads to fewer biopsies and potential savings

Multiparametric magnetic resonance imaging of the prostate (mpMRIp) is a promising tool for diagnosing prostate cancer, and prior to its availability, detection relied on clinical exams and prostate specific antigen screening.

In a study published in BJU International, investigators found that the availability of mpMRIp in Australia since 2012 has correlated with significantly reduced numbers of prostate biopsies by an average of 354.7 per month, with an estimated annual saving of $13.2 million.

Our research shows publicly funded prostate MRI not only represents good policy in terms of health equity, but it also makes sense from a financial perspective."

Thomas Whish-Wilson, BBiomedSc, MD, Lead Author, St Vincent's Hospital Melbourne and The University of Melbourne

Journal reference:

Whish‐Wilson, T., et al. (2020) Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer. BJUI.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
You might also like...
Researchers analyze the significance of cellular interactions for lung cancer